SECA Trial Challenges Routine Aspirin Cessation in Chronic Subdural Hematoma Surgery
核心洞察
The SECA randomized clinical trial found no significant difference in recurrence rates between patients who continued low-dose aspirin versus placebo after chronic subdural hematoma (搜索) surgery, with reoperation rates of 13.9% and 9.5% respectively.
Cardiovascular and thromboembolic event rates were similar between groups, but patients continuing aspirin experienced fewer cardiovascular events (0.02 vs 0.06 per person) over six months.
The findings challenge current practice patterns of routine aspirin discontinuation and suggest recurrence risks under continued aspirin therapy are lower than previously estimated from observational studies.
The SECA (Surgical Evacuation of Chronic Subdural Hematoma (搜索) and Aspirin) randomized clinical trial has challenged long-standing assumptions about perioperative aspirin management, demonstrating that discontinuing low-dose aspirin does not significantly reduce recurrence rates in patients undergoing chronic subdural hematoma (cSDH) surgery. The findings, published in JAMA Neurology, suggest that routine aspirin cessation may be unnecessary and could potentially elevate cardiovascular risks without providing meaningful bleeding protection.
Trial Design and Patient Population
The multicenter, placebo-controlled trial was conducted across six neurosurgical centers in Switzerland from 2018 to 2023, enrolling 155 adults aged 66 and older (mean age 77.7 years, 16% female) undergoing burr hole drainage for cSDH. All participants had pre-existing aspirin use for cardiovascular prevention and were randomized 1:1 to either continue aspirin (78 participants) or switch to placebo (77 participants) for 12 days surrounding surgery.
Primary Outcomes Show No Significant Difference
At six months follow-up, reoperation rates requiring surgical intervention were 13.9% in the aspirin group versus 9.5% in the placebo group, yielding a weighted risk difference of 4.4% (95% CI −7.2% to 15.9%; P=0.56). This difference was not statistically significant, contradicting the hypothesis that aspirin discontinuation would reduce recurrence rates.
"The SECA randomized clinical trial suggests that discontinuing ASA treatment did not reduce the recurrence rate of surgically treated cSDH within 6 months," noted lead author Maria Kamenova, MD, from the University of Basel. "Recurrence risk estimates for continuous ASA treatment in this trial were distinctly lower than previously reported."
Cardiovascular Risk Assessment
The trial revealed important insights regarding cardiovascular safety. Overall cardiovascular and thromboembolic event rates were similar between groups at 0.27 versus 0.28 per person half-year for aspirin and placebo groups, respectively. However, patients continuing aspirin experienced fewer aspirin-indicated cardiovascular events over six months (0.02 per person) compared to those receiving placebo (0.06 per person), suggesting a non-significant trend toward higher cardiovascular events with aspirin discontinuation.
Safety Profile and Bleeding Events
Minor bleeding events were slightly more common in the aspirin group (0.10 vs 0.08 per person in six months), while all-cause mortality rates were comparable between groups (0.06 vs 0.03 for aspirin and placebo, respectively). The relatively low bleeding rates observed challenge traditional concerns about hemorrhagic complications with continued antiplatelet therapy.
Clinical Implications and Practice Patterns
The results have significant implications for current clinical practice, where aspirin discontinuation upon admission has become routine despite limited high-quality evidence supporting this approach. Previous observational studies may have overestimated the hazards associated with continued aspirin therapy, as recurrence risks under continued aspirin in the SECA trial were distinctly lower than historical estimates.
Supporting Evidence from Meta-Analysis
A recent systematic review and meta-analysis in the British Journal of Neurosurgery, examining 44 studies with over 16,000 cSDH patients, found that patients taking anticoagulant or antiplatelet medications at baseline had higher recurrence rates and were more likely to experience serious thrombotic complications. However, the analysis highlighted insufficient evidence to guide safe timing for restarting these medications post-surgery, supporting the need for prospective data like the SECA trial provides.
Future Directions and Clinical Recommendations
The findings indicate that clinicians should prioritize individual thrombotic risk assessment over blanket aspirin cessation policies. The authors suggest that routine aspirin discontinuation may be unnecessary for cSDH surgery patients, as it fails to reduce recurrence while potentially elevating cardiovascular risks in this frail population.
Future research priorities include identifying high-recurrence patient subgroups and clarifying long-term cardiovascular impacts through larger trials powered for secondary endpoints. The development of risk stratification tools could help clinicians more effectively balance hemorrhagic and ischemic risks in perioperative management.
The SECA trial's findings support integrating these results into clinical guidelines to reduce unwarranted treatment interruptions and optimize outcomes in elderly patients with chronic subdural hematoma (搜索) requiring surgical intervention.